How does CBAY's PB Ratio compare to its peers?

CBAY is expensive based on its Price-To-Book Ratio (12.8x) compared to the peer average (9x).

How does CBAY's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

CBAY is expensive based on its Price-To-Book Ratio (12.8x) compared to the US Pharmaceuticals industry average (1.8x).

What is CBAY's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CBAY's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of CBAY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CBAY ($32.48) is trading below our estimate of [[fair value]] ($247.34)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

CymaBay Therapeutics (Nasdaq:CBAY) - Stock Price, News & Analysis

CBAY Stock Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. More details

CBAY fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 86.9% below our estimate of its fair value

Revenue is forecast to grow 50.87% per year

Risk Analysis

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

CymaBay Therapeutics, Inc. Competitors

Avadel Pharmaceuticals

NasdaqGM:AVDL

US$1.1b

Axsome Therapeutics

NasdaqGM:AXSM

US$4.7b

Nuvation Bio

NYSE:NUVB

US$972.7m

CorMedix

NasdaqGM:CRMD

US$593.4m

Price History & Performance

Summary of all time highs, changes and price drops for CymaBay Therapeutics
Historical stock prices
Current Share Price	US$32.48
52 Week High	US$32.50
52 Week Low	US$7.26
Beta	0.32
11 Month Change	0.87%
3 Month Change	40.67%
1 Year Change	262.91%
33 Year Change	607.63%
5 Year Change	147.94%
Change since IPO	260.89%

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22

Shareholder Returns

	CBAY	US Pharmaceuticals	US Market
7D	0.03%	3.4%	1.6%
1Y	262.9%	14.2%	32.3%

Return vs Industry: CBAY exceeded the US Pharmaceuticals industry which returned 25.3% over the past year.

Return vs Market: CBAY exceeded the US Market which returned 31.2% over the past year.

Price Volatility

Is CBAY's price volatile compared to industry and market?
CBAY volatility
CBAY Average Weekly Movement	8.2%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CBAY's share price has been volatile over the past 3 months.

Volatility Over Time: CBAY's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1988	101	Sujal Shah	www.cymabay.com

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes.

CymaBay Therapeutics, Inc. Fundamentals Summary

How do CymaBay Therapeutics's earnings and revenue compare to its market cap?
CBAY fundamental statistics
Market cap	US$3.73b
Earnings (TTM)	-US$105.37m
Revenue (TTM)	US$31.07m

120.0x

P/S Ratio

-35.4x

P/E Ratio

Is CBAY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CBAY income statement (TTM)
Revenue	US$31.07m
Cost of Revenue	US$80.80m
Gross Profit	-US$49.73m
Other Expenses	US$55.64m
Earnings	-US$105.37m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.92
Gross Margin	-160.03%
Net Profit Margin	-339.10%
Debt/Equity Ratio	37.4%

How did CBAY perform over the long term?

See historical performance and comparison

CBAY Stock Overview

Rewards

Risk Analysis

CymaBay Therapeutics, Inc. Competitors

NasdaqGM:AVDL

US$1.1b

NasdaqGM:AXSM

US$4.7b

NYSE:NUVB

US$972.7m

NasdaqGM:CRMD

US$593.4m

Price History & Performance

Recent News & Updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Recent updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Price target increased by 8.5% to US$31.07

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

Forecast to breakeven in 2026

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

Cymabay Therapeutics, Inc. Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

Price target increased by 7.5% to US$24.82

New minor risk - Profitability

CymaBay Therapeutics, Inc. Announces Publication of Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President exercised options and sold US$597k worth of stock

General Counsel notifies of intention to sell stock

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999939 million.

Price target increased by 17% to US$21.27

Insider notifies of intention to sell stock

Consensus revenue estimates increase by 156%

Price target increased by 8.0% to US$17.64

New minor risk - Profitability

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates fall by 15%

Price target increased by 8.5% to US$15.56

Insider notifies of intention to sell stock

Price target increased by 8.2% to US$14.67

New minor risk - Share price stability

Insider notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Consensus revenue estimates fall by 40%

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. Appoints Harish Shantharam as Chief Financial Officer

Executive Officer notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Price target increased by 11% to US$13.56

Price target increased by 8.1% to US$11.63

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999785 million.

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Cymabay Completes Enrollment for the Response Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from Russell 2000 Dynamic Index

CymaBay Therapeutics, Inc. Presents Positive PBC Data at the International Liver Congress 2022

President recently bought US$100k worth of stock

CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Price target decreased to US$10.50

Insufficient new directors

CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nominating and Corporate Governance Committee of the Board

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?